Jazz And Concert In Tune On Xyrem
This article was originally published in The Pink Sheet Daily
The two biotech companies have teamed up to create a follow-on product to Jazz’s narcolepsy drug, a collaboration that could add to the patent-life of Xyrem and be financially beneficial for both companies.
You may also be interested in...
Jazz will begin dispute resolution with FDA regarding the risk evaluation and mitigation strategy for its best-selling wakefulness drug.
Lexington, Mass.-based Concert became the second company studying deuterium chemistry in the current pipeline for initial public offerings. It joins Auspex, which updated its filing this week, as did pain drug developer Cara.
Concert Pharmaceuticals has garnered a third partnership for its deuterium-modification platform as the Massachusetts biotech continues to push its internal pipeline forward on its own.